# A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis

> **NCT06844799** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 720 (estimated)

## Conditions studied

- Moderate-to-severe Plaque Psoriasis

## Interventions

- **DRUG:** HS-20137
- **DRUG:** Placebo&HS-20137

## Key facts

- **NCT ID:** NCT06844799
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06844799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06844799, "A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06844799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*